B cell survival holds key to chronic graft vs. host disease

August 16, 2012

Leukemia and lymphoma patients who receive life-saving stem cell or bone marrow transplants often experience chronic side effects that significantly decrease quality of life, can last a lifetime, and ultimately affect their long-term survival.

In chronic Graft vs. Host Disease (GVHD), the differences between the donor and the recipient's body often cause these to recognize the recipient's body tissues as foreign and the newly transplanted cells attack the transplant recipient's body. Symptoms can range from dry eyes and dry mouth, hair loss and skin rashes, vulnerability to infection, liver and lung and digestive tract disorders. For patients who received bone marrow or stem cells, it is estimated that 40-70 percent may experience chronic GVHD.

, which produce proteins called antibodies, are one type of immune cell involved in GVHD. In a paper published in the journal, Blood, a team from the University of North Carolina's Lineberger Comprehensive Cancer Center, shows in the laboratory that B cells from patients with chronic GVHD are much more active than cells from patients without the disease. The team also outlines the that contribute to this increased activity – identifying a promising target for developing new therapies for the diseases.

Jessica Allen, PhD, the paper's first author, says "We found that B cells from patients with active chronic GVHD were in a heightened metabolic state and resist programmed cell death."

Senior author, Stefanie Sarantopoulos, MD, PhD, assistant professor in the division of hematology/oncology and the departments of microbiology and immunology at the UNC School of Medicine, adds, "Steroids are currently our only standard treatment for chonic GVHD and they are often not effective. This study adds to our previously published work because it implicates the TNF family member protein called BAFF in the 'revved up' B-cell signaling we found in our patients. We hope to develop targeted therapeutic agents, like anti-BAFF agents or small molecule inhibitors of serine/ threonine kinases, for treatment of our chronic GVHD patients."

Explore further: Bone marrow and blood stem cell transplant survival rates equal, when donor is unrelated to patient

Related Stories

Recommended for you

Researchers discover rare flu-thwarting mutation

September 29, 2016

A rare and improbable mutation in a protein encoded by an influenza virus renders the virus defenseless against the body's immune system. This University of Rochester Medical Center discovery could provide a new strategy ...

Utah man may have contracted Zika from dying father's tears

September 29, 2016

A Utah man who mysteriously contracted Zika from his infected father may have got it by touching his dad's tears or sweat with his bare hands, according to new research unveiled Wednesday that found the unusual transmission ...

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.